Tarsus Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

• Tarsus Pharmaceuticals Inc TARS.OQ reported a quarterly adjusted loss of 60 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-1.31. The mean expectation of nine analysts for the quarter was for a loss of 74 cents per share. Wall Street expected results to range from $-1.04 to -43 cents per share.

• Revenue rose 407.9% to $66.41 million from a year ago; analysts expected $58.33 million.

• Tarsus Pharmaceuticals Inc's reported EPS for the quarter was a loss of 60 cents​.

• The company reported a quarterly loss of $23.11 million.

• Tarsus Pharmaceuticals Inc shares had fallen by 17.8% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 4% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Tarsus Pharmaceuticals Inc is $72.50

This summary was machine generated from LSEG data February 25 at 02:32 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)